Literature DB >> 2942489

In vitro susceptibility of aerobic gram-negative blood culture isolates to oxolinic acid, norfloxacin, ciprofloxacin, enoxacin, pefloxacin, ofloxacin and oxo-enoxacin.

P Van der Auwera.   

Abstract

100 gram-negative strains isolated from blood cultures were selected for the evaluation of the in vitro activity of oxolinic acid, norfloxacin, ciprofloxacin, enoxacin, pefloxacin, ofloxacin and oxo-enoxacin. Ciprofloxacin showed the highest intrinsic activity. Oxo-enoxacin, the major metabolite of enoxacin, was 10-15-fold less active than enoxacin. Against Enterobacteriaceae and Vibrionaceae, all fluorinated quinolones except norfloxacin were equally effective, while against non-fermenters, ciprofloxacin and ofloxacin demonstrated greater activity than the others. Resistance to oxolinic acid had a detrimental effect on susceptibility to the new fluorinated quinolones.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2942489     DOI: 10.1007/bf01643481

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  18 in total

1.  In vitro activity of enoxacin compared with norfloxacin and amikacin.

Authors:  P van der Auwera; G de Moor; G Lacroix; A Mambour; N Rossion; F Schuyteneer
Journal:  Eur J Clin Microbiol       Date:  1985-02       Impact factor: 3.267

2.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

3.  The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.

Authors:  A King; K Shannon; I Phillips
Journal:  J Antimicrob Chemother       Date:  1984-04       Impact factor: 5.790

4.  [In vitro activity of seven gyrase inhibitors of a group of heterocyclic carbonic acids against nonfermenting gram negative rods (nonfermenters)].

Authors:  H Grimm
Journal:  Arzneimittelforschung       Date:  1985

5.  In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives.

Authors:  D L Van Caekenberghe; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

6.  In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.

Authors:  A Bauernfeind; C Petermüller
Journal:  Eur J Clin Microbiol       Date:  1983-04       Impact factor: 3.267

7.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

8.  Enoxacin: worldwide in-vitro activity against 22451 clinical isolates.

Authors:  C Siporin; G Towse
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

9.  Pharmacokinetics and tissue penetration of enoxacin.

Authors:  R Wise; R Lockley; J Dent; M Webberly
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

10.  [Comparative bacteriologic activity of norfloxacin, ofloxacin and pefloxacin against 320 Gram-negative bacilli resistant and non-resistant to nalidixic acid and cephalosporins].

Authors:  J Croize; P Le Noc; A Bryskier; J Robert
Journal:  Pathol Biol (Paris)       Date:  1985-06
View more
  4 in total

1.  Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment.

Authors:  P Van der Auwera; J C Stolear; B George; M N Dudley
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

2.  Concentrations of ofloxacin in serum and cerebrospinal fluid of patients without meningitis receiving the drug intravenously and orally.

Authors:  N Bitar; R Claes; P Van der Auwera
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

3.  High risk of streptococcal septicemia after high dose cytosine arabinoside treatment for acute myelogenous leukemia.

Authors:  W Kern; E Kurrle; E Vanek
Journal:  Klin Wochenschr       Date:  1987-08-17

4.  Ciprofloxacin and norfloxacin for selective decontamination in patients with severe granulocytopenia.

Authors:  G Maschmeyer; E Haralambie; W Gaus; W Kern; A W Dekker; H G De Vries-Hospers; W Sizoo; W König; F Gutzler; S Daenen
Journal:  Infection       Date:  1988 Mar-Apr       Impact factor: 3.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.